Gilead Sciences GILD has outperformed the market over the past 20 years by 3.74% on an annualized basis producing an average ...

**NM signifies a non meaningful value. A dash signifies the data is not available.

On the other hand, Gilead Sciences' revenue is growing nicely, at a compound rate of 4.8% over the last five years. It's ...

Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.

Discover why Gilead Sciences is a strong buy with potential blockbuster drugs in HIV and oncology, favorable valuation, and a ...

(Reuters) - Gilead Sciences said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously ...

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often ...

Gilead Sciences (GILD – Research Report) received a Buy rating and price target from Wells Fargo analyst Mohit Bansal today. The ...

Shares of Gilead Sciences Inc. GILD inched 0.33% higher to $84.95 Friday, on what proved to be an all-around great trading ...

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $77.91, along ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Positive clinical trial results for Merck & Co's experimental antiviral COVID-19 pill reverberated through the health care sector on Friday, sending the drugmaker's stock price soaring while ...